Spruce Biosciences (SPRB) +1,400% on FDA Breakthrough News

‍

Spruce Biosciences (SPRB) surged over 1,400% in one day after the U.S. FDA granted Breakthrough Therapy Designation for its experimental enzyme replacement therapy, Tralesinidase Alfa (TA-ERT), which targets Sanfilippo Syndrome Type B (MPS IIIB) — a rare and deadly genetic disorder.The designation fast-tracks development and review, signaling strong confidence in the drug’s potential and marking one of the biggest single-day gains for a biotech stock this year.

‍

Viomi Technology (VIOT) +20% on Earnings and Buyback News

‍

Viomi Technology Co., Ltd (VIOT) jumped 20% in one day after announcing that it will release its first-half 2025 financial results on November 10, 2025, alongside a new US$20 million share repurchase plan.

‍

Intel: Earnings, the White House stake, and the road to a real comeback

‍

Q3 recap. Intel is finally back in the black. The company reported $13.7 B in revenue (+3% YoY) and $0.23 in adjusted EPS, marking its first profit since 2023. But shares gave back early gains as investors focused on the tough road ahead.
‍

Debt and balance sheet. Intel repaid $4.3 B of debt last quarter and now holds about $30.9 B in cash and short-term investments. It also secured roughly $15 B in new capital — including a ~9.9% U.S. government stake (bought at $20.47 per share), $5 B from Nvidia, and $2 B from SoftBank. That funding, plus $5.7 B in U.S. government support already received, gives Intel breathing room to rebuild without taking on new debt.

‍

What’s working — and what still isn’t.
‍

• PC rebound: Laptop and desktop sales rose 5%, helping the quarter’s beat.
• Data Center & AI: Still down 1% YoY — Intel is struggling to catch up to Nvidia in AI chips.
• Foundry division: This is Intel’s manufacturing business — it makes chips for itself and (other companies in the future). Revenue was $4.2 B, but it still lost $2.3 B last quarter. That’s an improvement from a $5.8 B loss a year ago, but the division needs outside customers before it can turn profitable.
  ‍

Why the foundry matters.
‍
Intel wants to become America’s version of TSMC — the company that manufactures most of the world’s chips. If Intel can prove its “Intel 18A” production process works and win contracts from other chip designers, it can secure a long-term place in the global semiconductor supply chain and reduce U.S. dependence on Asia.

‍

Capital spending & capacity.
‍
Intel plans to spend about $18 B on new plants and equipment this year and will likely cut spending next year. Its massive Ohio fab project was pushed to the 2030s as Intel prioritizes stabilizing current operations.

‍